Belite Bio’s $36 Million IPO

Wilson Sonsini Goodrich & Rosati and O’Melveny advised Belite Bio on the deal.Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of its…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now